|Loss of PTEN promotes resistance to T cell–mediated immunotherapy|
W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ...
Cancer discovery 6 (2), 202-216, 2016
|Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy|
J Gao, LZ Shi, H Zhao, J Chen, L Xiong, Q He, T Chen, J Roszik, ...
Cell 167 (2), 397-404. e9, 2016
|A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade|
L Jerby-Arnon, P Shah, MS Cuoco, C Rodman, MJ Su, JC Melms, ...
Cell 175 (4), 984-997. e24, 2018
|Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients|
LG Radvanyi, C Bernatchez, M Zhang, PS Fox, P Miller, J Chacon, R Wu, ...
Clinical Cancer Research 18 (24), 6758-6770, 2012
|Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy|
T Cascone, JA McKenzie, RM Mbofung, S Punt, Z Wang, C Xu, ...
Cell metabolism 27 (5), 977-987. e4, 2018
|Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16–related cancer: a phase 2 clinical trial|
E Massarelli, W William, F Johnson, M Kies, R Ferrarotto, M Guo, L Feng, ...
JAMA oncology 5 (1), 67-73, 2019
|Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial|
T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ...
Nature medicine 27 (3), 504-514, 2021
|Oncogenic BRAF (V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma|
JS Khalili, S Liu, TG Rodríguez-Cruz, M Whittington, S Wardell, C Liu, ...
Clinical Cancer Research 18 (19), 5329-5340, 2012
|Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook|
R Wu, MA Forget, J Chacon, C Bernatchez, C Haymaker, JQ Chen, P Hwu, ...
The Cancer Journal 18 (2), 160-175, 2012
|Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer|
J Blando, A Sharma, MG Higa, H Zhao, L Vence, SS Yadav, J Kim, ...
Proceedings of the National Academy of Sciences 116 (5), 1692-1697, 2019
|Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues|
ER Parra, N Uraoka, M Jiang, P Cook, D Gibbons, MA Forget, ...
Scientific reports 7 (1), 13380, 2017
|Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.|
T Cascone, WN William, A Weissferdt, HY Lin, CH Leung, BW Carter, ...
Journal of Clinical Oncology 37 (15_suppl), 8504-8504, 2019
|Identification of bacteria-derived HLA-bound peptides in melanoma|
S Kalaora, A Nagler, D Nejman, M Alon, C Barbolin, E Barnea, ...
Nature 592 (7852), 138-143, 2021
|A first-in-human study and biomarker analysis of NKTR-214, a novel IL2Rβγ-biased cytokine, in patients with advanced or metastatic solid tumors|
SE Bentebibel, ME Hurwitz, C Bernatchez, C Haymaker, CW Hudgens, ...
Cancer discovery 9 (6), 711-721, 2019
|Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02)|
A Diab, NM Tannir, SE Bentebibel, P Hwu, V Papadimitrakopoulou, ...
Cancer discovery 10 (8), 1158-1173, 2020
|TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence|
A Reuben, R Gittelman, J Gao, J Zhang, EC Yusko, CJ Wu, R Emerson, ...
Cancer discovery 7 (10), 1088-1097, 2017
|Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function|
JA Hernandez-Chacon, Y Li, RC Wu, C Bernatchez, Y Wang, JS Weber, ...
Journal of immunotherapy 34 (3), 236-250, 2011
|Comprehensive T cell repertoire characterization of non-small cell lung cancer|
A Reuben, J Zhang, SH Chiou, RM Gittelman, J Li, WC Lee, J Fujimoto, ...
Nature communications 11 (1), 603, 2020
|BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma|
SD Bradley, Z Chen, B Melendez, A Talukder, JS Khalili, ...
Cancer immunology research 3 (6), 602-609, 2015
|Genetic and molecular characterization of uveal melanoma cell lines|
KG Griewank, X Yu, J Khalili, MM Sozen, K Stempke‐Hale, C Bernatchez, ...
Pigment cell & melanoma research 25 (2), 182-187, 2012